Article History
Received: 25 March 2024
Accepted: 30 April 2024
First Online: 14 May 2024
Declarations
:
: Salus IRB, 2111 W. Braker Lane, Ste 100, Austin, TX 78758, serves as the central ethics committee for this study (ITL-032-MCRC3-STIMVAX). Informed consent was obtained from all individual participants included in the study.
: The patient informed consent form provided consent to publish non-identifiable results.
: MHN is the inventor of the investigational AlloStim® product and is the founder of Mirror Biologics, Inc. which sponsored the clinical study. AH and DG declare that they have no competing interests.